CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Lorvotuzumab Mertansine (IMGN901)drug
Likely dose
Lorvotuzumab Mertansine (IMGN901) 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02420873
NCT02420873Phase 2Completed
CompareCT.gov

An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies

M.D. Anderson Cancer Center·interventional·Posted Apr 20, 2015·Updated Aug 28, 2018

In Brief

A Phase 2 clinical trial evaluating Lorvotuzumab Mertansine (IMGN901) for Leukemia. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsImmunoGen, Inc.

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 20, 2015
Enrollment StartMay 12, 2015
Primary CompletionJun 6, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.2 years ago

Interventions

Lorvotuzumab Mertansine (IMGN901)drug

100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.